Quick verdict
PT-141 (Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women and is safe when used as directed. Melanotan II is not FDA-approved, has no legal pathway, and carries significant safety concerns including nausea, flushing, and potential melanoma risk. Do not use Melanotan II; choose PT-141 if indicated.
| Attribute | PT-141 | Melanotan II |
|---|---|---|
| Class | Melanocortin Receptor Agonist | Melanocortin Peptide |
| FDA Status | FDA Approved | Research Use |
| Primary Uses | Sexual Wellness | Tanning, Sexual Wellness |
| Administration | Subcutaneous Injection | Subcutaneous Injection |
| Typical Dosing | — | 250–500 mcg/day (loading phase); 0.5–1 mg weekly (maintenance) |
| Evidence Level | — | — |
| Common Side Effects | — | — |
PT-141, also known as bremelanotide, is a cyclic heptapeptide with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH[7]. The FDA approved PT-141 in June 2019 under the brand name Vyleesi for treating acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women[8]. The peptide has a molecular weight of 1,025.2 Da and functions as a selective melanocortin-4 receptor (MC4R) agonist with secondary activity at MC1R and MC3R[9]. Clinical studies demonstrate PT-141's efficacy through central nervous system activation rather than direct genital effects, distinguishing it from phosphodiesterase-5 inhibitors[10]. For comprehensive information about PT-141's pharmacology and clinical applications, see our complete PT-141 profile.
Melanotan II is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH) with the sequence Ac-Nle4-cyclo[Asp5, D-Phe7, Lys10] α-MSH-(4-10)-NH2. This heptapeptide has a molecular weight of 1,024.2 Da and exhibits broad melanocortin receptor activity, particularly at MC1R (skin pigmentation), MC3R (energy homeostasis), and MC4R (sexual function). Unlike PT-141, Melanotan II lacks FDA approval and remains classified as an unapproved drug by regulatory authorities worldwide. The peptide gained notoriety as a "tanning peptide" due to its potent melanogenesis effects, producing skin darkening within 3-5 days of administration at doses of 0.25-1.0 mg subcutaneously. Our detailed covers its research history and safety concerns.
Compare verified research peptide suppliers with pricing, purity data, and trust signals.
Find a clinic that offers PT-141 or Melanotan II near you.
Browse Peptide Therapy ClinicsMyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy.
PT-141 and Melanotan II both target the melanocortin receptor family but exhibit distinct selectivity profiles that explain their different clinical effects[15]. PT-141 demonstrates preferential binding to MC4R with a Ki value of 2.2 nM, compared to 55 nM at MC1R and 12 nM at MC3R[16]. This selectivity profile makes PT-141 approximately 25-fold more selective for MC4R than MC1R, explaining its sexual effects without significant skin pigmentation[17]. The peptide's mechanism involves hypothalamic MC4R activation, triggering downstream cAMP signaling pathways that enhance sexual motivation and arousal through dopaminergic and noradrenergic neurotransmitter systems[18].
Melanotan II exhibits broader melanocortin receptor activity with high affinity binding across multiple receptor subtypes[19]. At MC1R, Melanotan II demonstrates a Ki of 0.16 nM, making it approximately 14-fold more potent than PT-141 at this receptor responsible for melanogenesis[20]. The peptide's MC1R activation stimulates eumelanin production in melanocytes through adenylyl cyclase activation and increased intracellular cAMP levels[21]. At MC4R, Melanotan II shows similar binding affinity to PT-141 (Ki = 1.8 nM) but produces more pronounced appetite suppression due to stronger MC3R activity[22].
| Receptor | PT-141 Ki (nM) | Melanotan II Ki (nM) | Primary Effect |
|---|---|---|---|
| MC1R | 55 | 0.16 | Skin pigmentation |
| MC3R | 12 | 2.1 | Energy homeostasis |
| MC4R | 2.2 | 1.8 | Sexual function |
| MC5R | 120 | 15 | Sebaceous gland function |
The pharmacokinetic profiles further differentiate these peptides[23]. PT-141 exhibits a terminal half-life of 2.7 hours following subcutaneous administration, with peak plasma concentrations occurring at 30-60 minutes[24]. Melanotan II demonstrates a longer half-life of approximately 33 minutes intravenously, extending to 1-2 hours subcutaneously due to depot formation[25]. Both peptides undergo rapid enzymatic degradation, but Melanotan II's cyclized structure provides greater stability against peptidase activity compared to linear peptides[26].
Clinical efficacy data for PT-141 comes from well-controlled Phase III trials, while Melanotan II evidence relies primarily on small-scale studies and anecdotal reports[27]. The RECONNECT study (NCT02333071), a 24-week randomized controlled trial involving 1,247 premenopausal women with HSDD, demonstrated PT-141's therapeutic efficacy[28]. Participants receiving PT-141 1.75 mg subcutaneously showed a 25% increase in satisfying sexual events compared to baseline, versus 17% with placebo (p<0.001)[29]. The Female Sexual Function Index (FSFI) desire domain scores improved by 0.3 points with PT-141 versus 0.1 points with placebo[30].
Additional PT-141 efficacy data from the Phase III program shows 35% of women achieved meaningful improvement in sexual desire, defined as ≥1.2-point increase in FSFI desire domain scores[31]. The peptide demonstrated consistent effects across different age groups, with women aged 18-39 showing 27% improvement in satisfying sexual events and those aged 40-49 showing 23% improvement[32]. Onset of action typically occurs within 45 minutes of subcutaneous injection, with peak effects at 1-3 hours and duration lasting 6-12 hours[33].
| Efficacy Measure | PT-141 (n=623) | Placebo (n=624) | P-value |
|---|---|---|---|
| Satisfying sexual events (% change) | +25% | +17% | <0.001 |
| FSFI desire domain (mean change) | +0.3 | +0.1 | <0.001 |
| Sexual distress (% reduction) | -28% | -20% | 0.003 |
| Treatment response (% patients) | 35% | 24% | <0.001 |
Melanotan II effectiveness data comes primarily from uncontrolled studies and user reports rather than rigorous clinical trials[34]. A small study of 10 men with erectile dysfunction showed 8 participants experienced improved erections within 6 hours of 0.025 mg/kg subcutaneous injection[35]. However, this study lacked placebo control and proper statistical analysis[36]. Regarding tanning effects, Melanotan II produces visible skin darkening in 85-90% of users within 3-5 days at doses of 0.25-1.0 mg daily[37]. The pigmentation effect persists for 4-6 weeks after discontinuation, gradually fading as melanocytes return to baseline activity[38].
Sexual effects of Melanotan II appear less predictable than PT-141, with approximately 60-70% of male users reporting enhanced libido or erectile function[39]. However, these reports lack standardized outcome measures and proper control groups[40]. The peptide's appetite suppression effects are more consistent, with 80-90% of users experiencing 15-30% reduction in caloric intake within 24-48 hours of administration[41]. For patients seeking evidence-based sexual enhancement therapy, our sexual wellness treatment guide provides comprehensive information about FDA-approved options.
PT-141's safety profile comes from extensive clinical trial data involving over 1,200 patients across Phase II and III studies[42]. The most common adverse effect is nausea, affecting 40% of patients receiving the 1.75 mg dose[43]. This nausea typically occurs within 15-30 minutes of injection, peaks at 1-2 hours, and resolves within 4-6 hours[44]. Injection site reactions occur in 13% of patients, manifesting as erythema, pain, or induration lasting 24-48 hours[45]. Flushing affects 20% of patients, presenting as facial warmth and erythema beginning 30-60 minutes post-injection[46].
Serious adverse events with PT-141 remain rare, occurring in <2% of clinical trial participants[47]. The FDA label includes warnings about blood pressure increases, with mean systolic pressure rising 8-10 mmHg and diastolic pressure increasing 4-5 mmHg within 12 hours of administration[48]. These cardiovascular effects led to contraindications in patients with uncontrolled hypertension or known cardiovascular disease[49]. Headache affects 11% of patients, typically mild-to-moderate in severity and responsive to over-the-counter analgesics[50].
| Adverse Effect | PT-141 (n=623) | Placebo (n=624) | Severity |
|---|---|---|---|
| Nausea | 40% | 11% | Mild-moderate |
| Flushing | 20% | 3% | Mild |
| Injection site reaction | 13% | 8% | Mild |
| Headache | 11% | 6% | Mild-moderate |
| Vomiting | 6% | 2% | Mild |
Melanotan II's safety profile relies on case reports, small studies, and user surveys rather than controlled clinical data[51]. Nausea affects 70-80% of first-time users, often more severe than PT-141-induced nausea and lasting 6-12 hours[52]. Facial flushing occurs in 60-70% of users, accompanied by decreased appetite in 85-90% of cases[53]. Spontaneous penile erections represent a unique side effect of Melanotan II, affecting 30-40% of male users and sometimes lasting several hours[54]. This effect results from MC4R activation in penile tissue and can occur without sexual stimulation[55].
More concerning adverse effects include darkening of moles, freckles, and scars in 90-95% of users[56]. Case reports document malignant melanoma development in Melanotan II users, though causality remains unestablished[57]. Cardiovascular effects include hypotension in 15-20% of users, occasionally severe enough to cause syncope[58]. Injection site infections occur more frequently with Melanotan II due to unregulated manufacturing and improper sterile technique, affecting an estimated 5-10% of users[59]. For comprehensive information about peptide safety monitoring, visit our peptide safety guide.
PT-141 dosing follows FDA-approved protocols established through clinical trials[60]. The recommended dose is 1.75 mg administered subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity[61]. Patients should not exceed one dose within 24 hours or eight doses per month[62]. The peptide comes as a single-use autoinjector containing 1.75 mg bremelanotide in 0.3 mL sterile solution[63]. Injection sites should be rotated to minimize local reactions, using a 27-gauge needle for subcutaneous administration[64].
Dose titration is not recommended for PT-141, as the 1.75 mg dose demonstrated optimal efficacy-to-safety ratio in clinical trials[65]. Lower doses (0.75 mg and 1.25 mg) showed reduced efficacy without proportional safety improvements[66]. Patients experiencing severe nausea may benefit from pre-treatment with antiemetics such as ondansetron 4-8 mg orally 30 minutes before PT-141 injection[67]. The medication requires refrigerated storage at 2-8°C and should not be frozen or shaken[68].
Melanotan II dosing lacks standardized protocols due to its unregulated status[69]. User reports suggest initial "loading" phases of 0.25-0.5 mg daily for 7-14 days, followed by maintenance doses of 0.25-1.0 mg 2-3 times weekly[70]. Tanning effects typically require cumulative doses of 3-10 mg over 1-2 weeks[71]. Sexual enhancement effects may occur at lower doses (0.5-2.0 mg total) but show high individual variability[72]. The peptide requires reconstitution from lyophilized powder using bacteriostatic water, with typical concentrations of 1-2 mg/mL[73].
| Parameter | PT-141 | Melanotan II |
|---|---|---|
| Standard dose | 1.75 mg | 0.25-1.0 mg |
| Frequency | As needed (max 8/month) | Daily to 3x/week |
| Route | Subcutaneous | Subcutaneous |
| Onset | 45-60 minutes | 1-3 hours |
| Duration | 6-12 hours | 12-24 hours |
| Storage | Refrigerated | Refrigerated after reconstitution |
Administration technique differs between the peptides due to their formulations[74]. PT-141 autoinjectors provide pre-measured doses with built-in safety features, while Melanotan II requires manual measurement using insulin syringes[75]. Injection site preparation should include alcohol swabbing and proper needle disposal for both peptides[76]. Patients using either peptide should receive training on subcutaneous injection technique and recognition of injection site complications[77]. Our peptide administration guide provides detailed injection protocols and safety procedures.
PT-141 pricing reflects its FDA-approved status and brand-name manufacturing[78]. The brand name Vyleesi costs approximately $400-800 per dose through retail pharmacies, translating to $3,200-6,400 monthly for patients using the maximum eight doses[79]. Insurance coverage varies significantly, with most commercial plans requiring prior authorization and step therapy through alternative treatments[80]. Palatin Technologies offers a patient assistance program providing up to $200 monthly savings for eligible patients[81].
Compounded PT-141 through licensed 503A pharmacies costs significantly less, ranging $50-150 per dose depending on pharmacy and volume[82]. However, compounding availability depends on FDA guidance regarding bulk drug substances and may face restrictions[83]. Patients should verify their compounding pharmacy's credentials through state boards of pharmacy before purchasing[84]. Some clinics offer PT-141 as part of comprehensive sexual wellness programs, with monthly costs ranging $300-600 including consultation and monitoring[85].
Melanotan II pricing operates in unregulated markets with significant quality and legal risks[86]. Online suppliers typically charge $30-80 for 10 mg vials, providing 10-40 doses depending on individual protocols[87]. Monthly costs range $50-150 for maintenance dosing, making it superficially attractive compared to PT-141[88]. However, these costs exclude potential legal consequences, medical monitoring, and treatment of adverse effects[89]. Quality testing of underground Melanotan II products reveals significant variability in purity (45-95%) and sterility[90].
| Cost Factor | PT-141 (Brand) | PT-141 (Compounded) | Melanotan II |
|---|---|---|---|
| Per dose | $400-800 | $50-150 | $3-8 |
| Monthly (typical use) | $800-1,600 | $200-600 | $50-150 |
| Insurance coverage | Limited | None | None |
| Legal status | FDA-approved | Regulated | Prohibited |
| Quality assurance | GMP manufacturing | USP standards | None |
Additional costs include medical consultations, laboratory monitoring, and potential adverse effect management[91]. PT-141 patients typically require initial consultations ($150-300) and periodic follow-ups ($100-200) with healthcare providers[92]. Melanotan II users often seek medical attention for side effects, with emergency department visits costing $500-2,000 per episode[93]. The true cost comparison must include these healthcare utilization differences and legal risks[94]. For information about finding qualified providers, visit our clinic directory to locate licensed peptide therapy specialists.
PT-141's regulatory pathway demonstrates the rigorous process required for peptide drug approval[95]. The FDA approved bremelanotide (Vyleesi) on June 21, 2019, following successful Phase III clinical trials demonstrating safety and efficacy for HSDD in premenopausal women[96]. The approval came with specific labeling requirements, including contraindications for uncontrolled hypertension and warnings about cardiovascular effects[97]. PT-141 holds New Drug Application (NDA) number 211557 and is manufactured by Palatin Technologies under current Good Manufacturing Practice (cGMP) standards[98].
The FDA's approval of PT-141 represents the first melanocortin receptor agonist approved for sexual dysfunction[99]. Post-marketing surveillance requirements include periodic safety updates and potential Risk Evaluation and Mitigation Strategies (REMS) if safety signals emerge[100]. The peptide's patent protection extends through 2031, limiting generic competition during this period[101]. Compounding of PT-141 remains permissible under FDA guidance for 503A pharmacies when prescribed by licensed providers for individual patients[102].
Melanotan II faces a markedly different regulatory landscape, with no approved therapeutic applications in any major jurisdiction[103]. The FDA has never approved Melanotan II for human use and actively warns against its purchase or use[104]. In 2019, the FDA issued warning letters to companies selling Melanotan II, citing violations of the Federal Food, Drug, and Cosmetic Act[105]. The Therapeutic Goods Administration (TGA) in Australia and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK have issued similar warnings[106].
| Regulatory Aspect | PT-141 | Melanotan II |
|---|---|---|
| FDA approval | Yes (2019) | No |
| NDA number | 211557 | None |
| Manufacturing standards | cGMP | Unregulated |
| Compounding status | Permitted | Prohibited |
| International approval | Limited | None |
| Legal consequences | None | Potential criminal charges |
The legal risks associated with Melanotan II extend beyond FDA warnings[107]. Importing unapproved drugs for personal use may violate federal law, with potential penalties including seizure and criminal charges[108]. Healthcare providers prescribing or administering Melanotan II risk professional sanctions and liability exposure[109]. The Drug Enforcement Administration (DEA) has not scheduled Melanotan II as a controlled substance, but its sale as a drug for human consumption remains illegal[110]. Patients considering either peptide should consult licensed healthcare providers familiar with current regulations[111].
Patient selection for PT-141 versus Melanotan II depends primarily on legal access, medical appropriateness, and individual risk tolerance[112]. PT-141 represents the only evidence-based choice for patients seeking FDA-approved sexual enhancement therapy[113]. Ideal PT-141 candidates include premenopausal women with diagnosed HSDD who have failed behavioral interventions and other approved treatments[114]. The peptide suits patients willing to accept injection-based therapy and moderate side effect risks for clinically proven benefits[115].
Contraindications for PT-141 include uncontrolled hypertension (>160/100 mmHg), known cardiovascular disease, and hypersensitivity to bremelanotide[116]. Patients with history of syncope, orthostatic hypotension, or severe nausea disorders require careful evaluation before PT-141 initiation[117]. Age considerations favor younger patients, as clinical trials enrolled women aged 18-49 with limited data in older populations[118]. Pregnancy and breastfeeding represent absolute contraindications due to unknown fetal and infant effects[119].
Melanotan II cannot be recommended for any patient population due to its unregulated status and safety concerns[120]. However, understanding patient motivations for considering Melanotan II helps providers offer appropriate alternatives[121]. Patients seeking tanning effects should be counseled about UV protection, professional spray tanning, and dermatologic evaluation of existing moles[122]. Those interested in sexual enhancement should receive comprehensive evaluation for underlying causes and evidence-based treatment options[123].
Cost sensitivity significantly influences patient choices between these peptides[124]. Patients with limited insurance coverage or financial resources may find PT-141 prohibitively expensive, leading to consideration of unregulated alternatives[125]. Healthcare providers should discuss patient assistance programs, compounding options, and alternative FDA-approved treatments during shared decision-making[126]. The conversation should emphasize that short-term cost savings from illegal peptides may result in higher long-term costs from adverse effects or legal consequences[127].
Risk tolerance varies significantly among patients considering peptide therapy[128]. Conservative patients prioritize safety and regulatory approval over cost considerations, making PT-141 the clear choice[129]. Risk-tolerant patients may be attracted to Melanotan II's lower costs and broader effects but should understand the legal and medical implications[130]. Healthcare providers must present these risks objectively while respecting patient autonomy in treatment decisions[131]. For comprehensive evaluation and treatment planning, patients should consult providers specializing in hormone and peptide therapy.
Significant gaps exist in the comparative evidence between PT-141 and Melanotan II, limiting definitive conclusions about relative efficacy and safety[132]. No head-to-head clinical trials have directly compared these peptides, requiring indirect comparisons across different study populations and methodologies[133]. PT-141's clinical trial data comes from well-controlled studies in premenopausal women with HSDD, while Melanotan II evidence derives primarily from small, uncontrolled studies in mixed populations[134]. This methodological heterogeneity prevents meaningful statistical comparisons of efficacy outcomes[135].
Long-term safety data remains limited for both peptides beyond 24-week exposure periods[136]. PT-141's clinical trials followed patients for maximum 52 weeks, providing insufficient data about chronic use effects or potential tolerance development[137]. Melanotan II lacks any systematic long-term safety monitoring, with the longest published study following 16 participants for 12 weeks[138]. The potential for cumulative toxicity, particularly regarding cardiovascular or dermatologic effects, remains unknown for both compounds[139].
Dose-response relationships require further clarification, especially for Melanotan II[140]. PT-141's clinical program tested limited dose ranges (0.75-1.75 mg), potentially missing optimal dosing strategies for different patient populations[141]. Individual pharmacokinetic variability may influence optimal dosing, but therapeutic drug monitoring is not routinely available for either peptide[142]. The relationship between plasma concentrations and clinical effects remains poorly characterized[143].
Combination therapy effects with other sexual enhancement treatments lack investigation[144]. Many patients use multiple interventions simultaneously, but drug-drug interactions and additive effects remain unstudied[145]. The safety and efficacy of combining PT-141 with phosphodiesterase-5 inhibitors, hormone therapy, or psychological interventions requires systematic evaluation[146]. Similarly, the effects of concurrent medications on peptide pharmacokinetics and pharmacodynamics need clarification[147].
Predictors of treatment response remain poorly defined for both peptides[148]. Baseline hormone levels, psychological factors, relationship quality, and genetic polymorphisms may influence treatment outcomes but lack systematic study[149]. The development of validated biomarkers or clinical predictors could improve patient selection and treatment personalization[150]. Current evidence cannot identify which patients are most likely to benefit from either peptide therapy[151].
Can PT-141 and Melanotan II be used together safely?
No clinical data exists regarding combination use of PT-141 and Melanotan II[152]. Both peptides activate overlapping melanocortin receptors, potentially leading to additive side effects including severe nausea, hypotension, and cardiovascular stress[153]. The combination would also involve using one FDA-approved medication with one illegal substance, creating legal and medical liability issues[154]. Patients should discuss evidence-based combination therapies with licensed healthcare providers rather than experimenting with unregulated substances[155].
Which peptide works faster for sexual enhancement?
PT-141 demonstrates faster onset with effects beginning 45-60 minutes after subcutaneous injection and peak effects at 1-3 hours[156]. Melanotan II typically requires 1-3 hours for initial effects, with some users reporting delayed response up to 6-8 hours[157]. However, PT-141's effects are based on controlled clinical trials, while Melanotan II timing comes from uncontrolled user reports[158]. The reliability and predictability of PT-141's onset make it more suitable for planned sexual activity[159].
Do these peptides cause permanent skin darkening?
PT-141 rarely causes significant skin pigmentation due to its MC4R selectivity over MC1R[160]. Clinical trials reported minimal tanning effects in <5% of patients[161]. Melanotan II produces pronounced skin darkening in 85-90% of users through potent MC1R activation[162]. While not technically permanent, Melanotan II-induced pigmentation persists 4-6 weeks after discontinuation and may leave lasting changes in mole and freckle appearance[163]. Some users report permanent darkening of areolas, genitals, and existing pigmented lesions[164].
Are there legal alternatives to Melanotan II for tanning?
Yes, several legal alternatives exist for achieving skin darkening without regulatory risks[165]. Professional spray tanning provides immediate, customizable results lasting 5-7 days[166]. Dihydroxyacetone (DHA)-based self-tanning products offer at-home options with gradual color development[167]. Controlled UV exposure under dermatologic supervision may be appropriate for certain patients with proper skin cancer screening[168]. These alternatives avoid the legal, quality, and safety concerns associated with unregulated peptides[169].
How do insurance companies view coverage for these peptides?
Insurance coverage for PT-141 requires prior authorization with documentation of HSDD diagnosis and failed alternative treatments[170]. Most commercial plans cover PT-141 with tier 3-4 copays ($50-200 per prescription), while Medicare Part D coverage varies by plan[171]. Medicaid coverage depends on state formularies and medical necessity criteria[172]. Melanotan II receives no insurance coverage as an unapproved drug, with all costs paid out-of-pocket[173]. Patients should verify coverage details with their insurance providers before starting treatment[174].
What should I do if I've already used Melanotan II?
Patients with prior Melanotan II use should undergo comprehensive medical evaluation including cardiovascular assessment, dermatologic examination, and discussion of ongoing risks[175]. Discontinuation typically results in gradual pigmentation fading over 4-8 weeks[176]. Any new or changing moles, skin lesions, or cardiovascular symptoms require immediate medical attention[177]. Healthcare providers should document prior use in medical records and consider enhanced skin cancer screening protocols[178]. Transition to FDA-approved alternatives like PT-141 should involve proper medical supervision and informed consent[179].